NCT01536041 - A Placebo and Active Controlled Study of ONO-6950 in Asthmatic Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

November 30, 2012

Conditions

Asthma

Interventions

DRUG

ONO-6950

200 mg QD, single dose

DRUG

ONO-6950

20 mg QD, single dose

DRUG

Montelukast

10 mg Montelukast, QD single dose

DRUG

Placebo

Placebo to match ONO-6950 tablets or leukotriene receptor antagonist (LTRA) tablets dosed in a similar manner

Trial Locations (9)

Raleigh Clinical Site 130, Raleigh

Minneapolis Clinical Site 190, Minneapolis

New Braunfeis Clinical Site 120, New Braunfels

San Antonio Clinical Site 180, San Antonio

Denver Clinical Site 160, Denver

Los Angeles Clinical Site 110, Los Angeles

San Diego Clinical Site 140, San Diego

North Dartmouth Clincial Site 150, North Dartmouth

Princeton Clinical Site 170, Princeton